Beyond vision and roadmaps, a CPO’s fundamental role is to act as a steward of the company's R&D investment. The primary measure of success is the ability to ensure that every dollar spent on development translates into tangible, measurable enterprise value for the business.

A CEO's primary role differs fundamentally based on company type. In an asset-centric biotech, the CEO must act as a hands-on program manager, micromanaging execution. In a platform company, the CEO must be deeply embedded in the science to predict and leverage the technology's long-term trajectory.

Enara Bio's discovery platform wasn't outsourced. It was built internally with integrated computational biology, mass spectrometry, and immunology teams. The CEO believes the most significant innovation and "magic" happens at the interface between these disciplines, a synergy only possible with close internal collaboration.

A three-fold increase in Chief Product Officer roles over the last decade, with few Chief Project Officer counterparts, highlights a strategic leadership shift. The C-suite is prioritizing ongoing product value and market fit over the execution of discrete, time-bound projects.

The CEO of NervGen explicitly states his goal is to commercialize their spinal cord injury drug independently, not to position the company for an acquisition. This long-term, mission-driven focus on getting a drug to market shapes strategic decisions and contrasts with a common build-to-sell mentality in biotech.

Many biotechs start with a single technology to solve a single problem. Dispatch Bio's co-founders believed a superior company could be created with a suite of technologies that addresses numerous field observations at once, creating a more robust therapeutic platform.

In the early stages, a biotech CEO's role is primarily scientific leadership and storytelling to attract investors. As the company and market mature, the role shifts. Effective CEOs must then become adaptable strategists, staying true to their core vision while responding to the dynamic industry environment.

Early-stage biotechs prioritize scientists to build the core platform. However, once a lead clinical program is identified, the critical hire becomes a Chief Medical Officer who can design the clinical strategy. This hire is timed to the program's maturation, not the company's age, reflecting a pivotal strategic shift.

The CPO's responsibilities have expanded from product roadmaps to key business decisions like go-to-market strategy, partnerships, and defining the company's core focus. This strategic voice is becoming central to the C-suite, sometimes even before a CTO or CMO is hired.